Trial · NCT07893171
Study of CM529D1 in Participants With Advanced Solid Tumors
NCT07893171, Phase 1, Phase 2, Not yet recruiting, Keymed Biosciences Co.Ltd
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of CM529D1 in Participants With Advanced Solid Tumors. Trials, record NCT07893171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893171
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of CM529D1 in Participants With Advanced Solid Tumors
- NCT number
- NCT07893171
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Keymed Biosciences Co.Ltd
- Conditions
- Advanced Solid Tumors
- Interventions
- CM529D1, CM529D1, CM529D1
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Limiting Toxicity (DLT)-Phase I dose escalation | First cycle (21 days) | DLT is defined as a toxicity occurring during the DLT observation period. |
| Primary | Incidence of adverse events (AEs), serious adverse events (SAEs), and specific laboratory abnormalities-Phase I dose escalation | Through study completion, an average of 2 years | An adverse event is defined as any unfavorable medical event that occurs in a subject after receiving the investigational drug, which will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v6.0 criteria. |
| Primary | The Recommended Phase 2 Dose (RP2D)Phase I dose expansion | Through study completion, an average of 2 years | RP2D is defined as the dose selected at the conclusion of Phase 1 dose- expansion, based on the integrated assessment of safety, tolerability, pharmacokinetics, and preliminary antitumor activity, and recommended for further evaluation in Phase 2 studies. |
| Primary | Objective response rate (ORR)-Phase II | Through study completion, an average of 2 years | ORR is defined as the proportions of subjects with a complete response (CR) and partial response (PR). ORR will be assessed by investigator according to Response Evaluation Criteria in Solid Tumors( RECIST) v1.1. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893171
GET https://conductscience.org/api/trials/v1/NCT07893171/registered